Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Summary

This randomized phase II trial studies how well bevacizumab with or without anti-endoglin monoclonal antibody TRC105 (TRC105) works in treating patients with kidney cancer that has spread to other parts of the body (metastatic). Monoclonal antibodies, such as bevacizumab and anti-endoglin monoclonal antibody TRC105, may block tumor growth in different ways by targeting certain cells.

Timeline

Start

2012-11-01

Primary completion

2017-08-08

Completion

2017-08-08

Drugs

Indications